Related Experiment Video

Updated: Oct 7, 2025

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.7K

LTK fusions: A new target emerges in non-small cell lung cancer

Alissa J Cooper1, Lecia V Sequist1, Ted W Johnson2

  • 1Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Cancer Cell
|January 11, 2022
PubMed

Insights

Researchers discovered a new CLIP1-LTK fusion in lung cancer. This fusion is an oncogenic driver and can be targeted by the ALK inhibitor lorlatinib, offering a new therapeutic option.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targetable genetic fusions are key oncogenic drivers in non-small cell lung cancer (NSCLC).
  • Identifying novel fusions transforms the diagnostic and therapeutic landscape of lung cancer.

Purpose of the Study:

  • To report the discovery of a novel CLIP1-LTK fusion in lung cancer.
  • To investigate the oncogenic role of the CLIP1-LTK fusion.
  • To evaluate the efficacy of targeted therapy against this fusion.

Main Methods:

  • Fusion gene identification in lung cancer patient samples.
  • Functional studies to confirm oncogenic potential.
  • In vitro and in vivo testing of targeted inhibitors.

Main Results:

  • Discovery of the CLIP1-LTK fusion as a novel oncogenic driver in lung cancer.
  • Demonstration that the CLIP1-LTK fusion is sensitive to the ALK tyrosine kinase inhibitor lorlatinib.

Conclusions:

  • The CLIP1-LTK fusion represents a new actionable target in NSCLC.
  • Lorlatinib shows promise for treating lung cancers harboring the CLIP1-LTK fusion.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
712